With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.   Oncology Data Advisor: Welcome to Oncology Data Advisor. Tod...

Despite the many obstacles associated with treating and managing patients with metastatic colorectal cancer, the ongoing study of several novel agents has the potential to significantly improve the outcomes of these patients in the coming years. In this interview, Tanios Bekaii-Saab, MD, Professor of Medicine at the Mayo Clinic Cancer Center in Phoenix, Arizona, discusses strategies to optimize the management of metastatic colorectal cancer and the promising developments which may advance treatm...

Gregg L. Semenza, MD, PhD, was recently awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work in isolating hypoxia inducible factor (HIF) 1, which controls genes that are involved in cells' adaptation to low oxygen levels, with implications for cancer, ischemia, and chronic lung disease. In this interview with i3 Health, Dr. Semenza discusses the involvement of HIF-1 and HIF-2 in cancer and shares insights on the progress that is being made in developing HIF-1 and HIF-2 i...

Chemotherapy is an effective treatment for many cancers; however, the side effects can have huge consequences, especially on pediatric patients, who are still growing. In particular, children treated for medulloblastoma—the most common malignant pediatric brain tumor—have devastating lifelong side effects from chemotherapy. Less harmful treatments are needed. In a new study published in Nature Communications, scientists have discovered that inhibiting an epigenetic modifier protein called lysine...

The old model of cancer treatments consisted of administering nonspecific cytotoxic therapies to various cancer patients. Now, cancer treatment has evolved to include agents that target a patient's genome and immune system, resulting in better patient outcomes. This 'precision medicine' approach individualizes treatment depending on each patient's unique tumor. Researchers discovered that using precision medicine to select combination treatments that target more than one genomic alteration is ef...

​Researchers have developed a portable system that quickly determines an individual patient's response to targeted cancer therapy. "Our technology combines artificial intelligence and sophisticated biosensors that handle tiny amounts of fluids to see if cancer cells are sensitive or resistant to chemotherapy drugs," commented Mehdi Javanmard, PhD, Assistant Professor of Electrical and Computer Engineering at Rutgers University–New Brunswick and senior author of the study, which has now been publ...